CLOs on the Move

Kytopen

www.kytopen.com

 
Kytopen is a biotechnology company that offers a customizable yet scalable multi-solution platform, which seamlessly links the discovery, development, and manufacturing phases of cell engineering. Their patent-pending technology, Flowfect®, enables tra...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kytopen.com
  • 750, Main Street
    Cambridge, MA USA 02139
  • Phone: 443.799.3072

Executives

Name Title Contact Details

Similar Companies

Careteam Plus

Careteam Plus provides compassionate, inclusive general and specialty health care for adults, teens, and children in Conway near CCU.

SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc. is a Foster City, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Global Research Services

Global Research Services is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bellicum

Bellicum Pharmaceuticals, located near the Houston Medical Center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. We are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT) and CAR T cell therapy. We are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.

BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.